ARCHIVES

Clinical Sciences Director Liu To Head Singapore Program.

This article is from The Cancer Letter archive.

Vol. 27 No. 02 | January 12, 2001

Download PDF Visit The Full Archive

Related Articles

Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds

August 26, 2005

Breast Cancer Low Fat Investigators to Seek R01 Funds for New Compliance, Biochemical Studies

April 25, 1986

NTP Panel Agrees PBB Carcinogenic, Two Asbestos Varieties Are Not

July 3, 1981

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

December 26, 2014

FDA News: Tentative Approval Given IVAX Paxene; BMS Exclusivity Upheld

January 9, 1998

Salmon Enthusiastic About Comprehensive Core Grant Plan

May 6, 1988